Literature DB >> 20544686

Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma.

Sherien F El-Shazly1, Manal A Eid, Hesham A El-Sourogy, Gehan F Attia, Sherif A Ezzat.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignancy in Egypt due to the high frequency of hepatitis C virus (HCV) infection among the general population. Circulating free DNA is a potential molecular marker for the diagnosis and prognosis of malignant tumors. DNA released from apoptotic cells usually consists of short uniform fragments while DNA released from cancer cells is longer. The ratio of long DNA fragments to total DNA (DNA integrity) may be a potential marker for early detection of HCC and its progression in HCV patients.
METHODS: Sera from 25 patients with HCV-related HCC, 25 patients with chronic HCV infection, and 15 healthy volunteers were examined for Alu repeats by quantitative real-time PCR (qPCR) using 2 sets of primers of 115 and 247 base pairs. DNA integrity was calculated as the ratio of 247-bp to 115-bp Alu fragments.
RESULTS: Compared with healthy volunteers and HCV patients, significantly higher DNA integrity was found in HCC patients. DNA integrity was associated with tumor size, TNM stage, vascular invasion, lymph node involvement, and distant metastasis. DNA integrity had a higher sensitivity and specificity in discriminating HCC from HCV patients than total DNA. Patients with high DNA integrity had a significantly shorter overall survival and high DNA integrity was shown to be an independent prognostic factor for survival in HCV-related HCC.
CONCLUSIONS: DNA integrity is a promising molecular biomarker for detecting HCC in patients with chronic HCV infection; it reflects the progression and metastatic potential of the tumor, and high DNA integrity is associated with short overall survival in HCV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544686     DOI: 10.1177/172460081002500204

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  11 in total

Review 1.  The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Authors:  Jessica A Howell; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-11-30

2.  Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.

Authors:  Azza M Kamel; Salwa Teama; Amal Fawzy; Mervat El Deftar
Journal:  Tumour Biol       Date:  2015-12-18

Review 3.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.

Authors:  Vincent L Chen; Dabo Xu; Max S Wicha; Anna S Lok; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-11       Impact factor: 11.382

4.  Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis.

Authors:  Wenjun Liao; Yilei Mao; Penglei Ge; Huayu Yang; Haifeng Xu; Xin Lu; Xinting Sang; Shouxian Zhong
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

5.  Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer.

Authors:  Sobuhi Iqbal; Sreenivas Vishnubhatla; Vinod Raina; Surabhi Sharma; Ajay Gogia; Suryanarayana S V Deo; Sandeep Mathur; Nutan Kumar Shukla
Journal:  Springerplus       Date:  2015-06-17

Review 6.  Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook.

Authors:  Charlotte K Y Ng; Giovan Giuseppe Di Costanzo; Luigi M Terracciano; Salvatore Piscuoglio
Journal:  Front Med (Lausanne)       Date:  2018-03-26

Review 7.  The Prospect and Challenges to the Flow of Liquid Biopsy in Africa.

Authors:  Dada Oluwaseyi Temilola; Martha Wium; Tangbadioa Herve Coulidiati; Henry Ademola Adeola; Giuseppina Maria Carbone; Carlo Vittorio Catapano; Luiz Fernando Zerbini
Journal:  Cells       Date:  2019-08-09       Impact factor: 6.600

Review 8.  Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Authors:  Filippo Pelizzaro; Romilda Cardin; Barbara Penzo; Elisa Pinto; Alessandro Vitale; Umberto Cillo; Francesco Paolo Russo; Fabio Farinati
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

9.  Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma.

Authors:  Ao Huang; Xin Zhang; Shao-Lai Zhou; Ya Cao; Xiao-Wu Huang; Jia Fan; Xin-Rong Yang; Jian Zhou
Journal:  J Cancer       Date:  2016-08-12       Impact factor: 4.207

10.  Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).

Authors:  Shilpa Thakur; Andrew Tobey; Brianna Daley; Sungyoung Auh; Mary Walter; Dhaval Patel; Naris Nilubol; Electron Kebebew; Aneeta Patel; Kirk Jensen; Vasyl Vasko; Joanna Klubo-Gwiezdzinska
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.